eatg.org·3 min read·hard
[AIDS 2026] aidsmap: Alternative first-line HIV regimen limits excess weight gain
H
https://www.facebook.com/EuropeanAIDSTreatmentGroup![[AIDS 2026] aidsmap: Alternative first-line HIV regimen limits excess weight gain](/api/imagekit?u=https%3A%2F%2Fwww.eatg.org%2Fwp-content%2Fuploads%2F2023%2F11%2F53404.jpg&w=3840&q=75)
✦AI Summary
A South African study presented at AIDS 2026 suggests that starting HIV treatment with doravirine and tenofovir disoproxil leads to less weight gain than standard regimens containing dolutegravir. Researchers are exploring alternative drug combinations to mitigate the common side effect of weight gain in patients.
Starting treatment with a regimen containing doravirine and tenofovir disoproxil resulted in less weight gain than starting treatment with a regimen containing dolutegravir and tenofovir alafenamide, a South African study reported at AIDS 2026.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in